Should an Institution That Has Commercial Rights in a New Drug or Device Be Allowed to Evaluate the Technology?

Ross McKinney and David Korn

PLOS Medicine, 2005, vol. 2, issue 1, 1-

Abstract: : In the United States, the passage of the Bayh–Dole Act in 1980 encouraged universities to license inventions for commercial development. Although this financial incentive can stimulate academic researchers to discover new drugs and devices, there is concern that the possibility of monetary reward could distort investigators' objectivity. In the US, universities are encouraged to license inventions for commercial development. Although this financial incentive can stimulate academics to discover new treatments, it might also distort the investigators' objectivity.

Date: 2005
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0020009 (text/html)
https://journals.plos.org/plosmedicine/article/fil ... 20009&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pmed00:0020009

DOI: 10.1371/journal.pmed.0020009

Access Statistics for this article

More articles in PLOS Medicine from Public Library of Science
Bibliographic data for series maintained by plosmedicine ().